Vusolimogene oderparepvec
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors.
The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Vusolimogene oderparepvec was approved for medical use in the United States in August 2026.
Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors.
The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Vusolimogene oderparepvec was approved for medical use in the United States in August 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376991482 under CC BY-SA 4.0; modifications have been made.